Derniers articles

Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial

AbstractBackground and objective: The CABASTY study showed that more frequent administration of a lower dose of...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : European Urology Oncology

New Biomarkers to Define A Biological Borderline Situation for Pancreatic Adenocarcinoma - Results of An Ancillary Study of the PANACHE01-PRODIGE48 Trial.

AbstractObjective: To investigate in patients treated for a resectable pancreatic ductal adenocarcinoma (PA), the...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Annals of Surgery

A comparison of target volumes drawn on arterial and venous phase scans during radiation therapy planning for patients with pancreatic cancer: the PANCRINJ study

AbstractBackground: The planification of radiation therapy (RT) for pancreatic cancer (PC) requires a dosimetric...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Radiation Oncology

A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial

AbstractBackground: We assessed the added value of incorporating carcinoembryonic antigen (CEA) to circulating...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : The Oncologist

Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort

AbstractKeywords: Biliary tract cancer; CisGem; Molecular profile; Real-life data.

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Digestive and Liver Disease

Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer

AbstractContext and aims: Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast...

Posté par : Dr. Dewi VERNEREY, Mr. Antoine FALCOZ
Nom de la revue : Clin Breast Cancer.

Interaction analysis of subgroup effects in randomized trials: the essential methodological points

AbstractSubgroup analysis aims to identify subgroups (usually defined by baseline/demographic characteristics), who...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Sci Rep.

Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study

AbstractBackground: Stage II colon cancer (CC) exhibits considerable prognostic heterogeneous. Our objective was to...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Clin Colorectal Cancer.

Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases

AbstractBackground: Small bowel adenocarcinoma is a rare disease. The genomic profiling tumours according to...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Br J Cancer.

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability

AbstractBackground: One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer.

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study

AbstractBackground: The modified docetaxel, cisplatin, and fluorouracil (mDCF) regimen has shown efficacy and...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol.

Does Kono-S Anastomosis Reduce Recurrence in Crohn's Disease Compared with Conventional Ileocolonic Anastomosis? A Nationwide Propensity Score-matched Study from GETAID Chirurgie Group [KoCoRICCO Study]

AbstractBackground and aims: Postoperative recurrence is a major concern in Crohn's disease. The Kono-S anastomosis...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : J Crohns Colitis.

Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort

AbstractBackground & aims: Accumulating data has shown the rising incidence and poor prognosis of early-onset...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Liver Int.

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer

AbstractBackground: It is intuitively thought that early relapse is associated with poor survival after recurrence...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer.

KONO-S Anastomosis Is Not Superior to Conventional Anastomosis for the Reduction of Postoperative Endoscopic Recurrence in Crohn's Disease

AbstractBackground: Surgical resection rates remain high in Crohn's disease (CD). Reducing postoperative recurrence...

Posté par : Dr. Dewi VERNEREY, Mr. Antoine FALCOZ
Nom de la revue : Inflamm Bowel Dis.

Transfused Red Blood Cell Characteristics and Kidney Transplant Outcomes Among Patients Receiving Early Posttransplant Transfusion

AbstractImportance: Red blood cell transfusion (RBCT) is frequently required in the early post-kidney transplant...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : JAMA Netw Open

Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study

AbstractBackground: Small bowel adenocarcinoma is a rare cancer, and the role of adjuvant chemotherapy for...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : JNCI Cancer Spectr.

Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

AbstractAims: The EXTREME regimen is the standard for recurrent and/or metastatic head and neck squamous cell...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Clin Oncol (R Coll Radiol)

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)

AbstractBackground: Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study

AbstractTriplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Exp Hematol Oncol

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma

AbstractPurpose: The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol .

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study

AbstractPurpose: Baseline circulating tumour DNA (ctDNA) is a potential prognostic marker in metastatic colorectal...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

État des lieux des pratiques de prise en charge des cancers des voies biliaires en France : résultats de l'enquête nationale ACABi

AbstractOverview of biliary tract cancer management practices in France: results of the ACABi national survey...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Bull Cancer

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

AbstractBackground: Trastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Front Cardiovasc Med

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study

AbstractPurpose: Universal cancer peptide-based vaccine (UCPVax) is a therapeutic vaccine composed of two highly...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : J Clin Oncol

Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?

AbstractBackground: We evaluated the value of pre-treatment positron-emission tomography-computed tomography...

Posté par : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Cancers (Basel)

Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review

AbstractBackground: Overall response rate (ORR) and progression-free survival (PFS) are commonly used as endpoints...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Clin Res Hepatol Gastroenterol

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

AbstractPurpose: In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Journal of Clinical Oncology

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T H 1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

AbstractBackground: There is a strong rational of using anti-programmed cell death protein-1 and its ligand...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Front Oncol

Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study"

AbstractIntroduction: Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clinical colorectal cancer

Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study

AbstractPurpose: This prospective pharmacokinetic (PK) ancillary study of the TEXCAN phase II GERCOR trial of...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : European journal of cancer

Early Post-Transplant Red Blood Cell Transfusion Is Associated With an Increased Risk of Transplant Failure: A Nationwide French Study

AbstractBackground: Red blood cell (RBC) transfusions are frequently required in the early period after kidney...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Frontiers in oncology

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer

AbstractBackground: There is a paucity of data regarding the prognostic influence of peripheral blood CD4+ T...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : BMC cancer

Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)

AbstractBackground: Histological characteristics at the invasive front may reflect tumor aggressiveness;...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Annals of oncology

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia

AbstractIntroduction: Survivors of viral ARDS are at risk of long-term physical, functional and neuropsychological...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Annals of Intensive Care

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

AbstractBackground: Studies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Frontiers in oncology

Is it safe to perform an anastomosis for rectal cancer after prostate cancer? A multicentre study of 126 patients from the GRECCAR group

AbstractAim: To determine the safety of performing an anastomosis after rectal cancer (RC) resection in patients...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Colorectal Dis

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

AbstractBackground: Squamous cell carcinoma of the anus (SCCA) is a rare disease often diagnosed at a localised...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study

AbstractIn the era of immune checkpoint inhibitors, understanding the metastatic microenvironment of proficient mismatch...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Mol Oncol

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

AbstractPurpose: Early-onset (EO) colorectal cancer (CRC, age < 50 years) incidence is increasing. Decisions on...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol

Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey

AbstractBackground: Adjuvant chemotherapy use in stage II colon cancer is controversial. Current prognostic risk...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Cancers (Basel)

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

AbstractHigh-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous...

Posté par : Mme. Julie HENRIQUES, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Cancers (Basel)

Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort

AbstractBackground: Metastatic signet-ring cell colorectal carcinoma is rare. We analyzed its clinicopathological...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Dig Liver Dis

Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post-hoc analysis of the PRODIGE-GERCOR IDEA-France trial

AbstractPurpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clin Cancer Res .

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma

AbstractBackground: Surgical resection with adjuvant chemotherapy is the only treatment that can provide long term...

Posté par : Dr. Dewi VERNEREY, ,
Nom de la revue : Front Oncol

Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

AbstractCirculating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Mol Oncol .

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

AbstractBackground: The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients,...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Ann Oncol

Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma

AbstractKeywords: RTQA; chemoradiotherapy; locally advanced; pancreatic adenocarcinoma; quality control; radiation...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Int J Radiat Oncol Biol Phys

Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma

AbstractPurpose: Baseline neutrophil count may predict overall survival (OS) in patients with locally advanced...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Int J Radiat Oncol Biol Phys

Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. Large genomic analyses with prognostic assessments are...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

AbstractAims: The addition of docetaxel to cisplatin and 5-fluorouracil (DCF) has shown promising efficacy in...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Ther Adv Med Oncol

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

AbstractBackground: The IMMUNOBIL PRODIGE 57 trial is a non-comparative randomized phase II study assessing the...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

AbstractFluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

AbstractBackground: A prospective, pooled analysis of six randomised phase 3 trials was done to investigate...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial

In their recent article in Journal of Clinical Oncology regarding the InterAAct phase II trial in advanced...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol

11 November, 2020

Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients

AbstractBackground: Randomized controlled trials (RCTs) represent the best evidence in oncology research....

Posté par : Mr. Antoine FALCOZ, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY
Nom de la revue : Neurooncol Pract

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

AbstractBackground: Immune checkpoint inhibitors (ICIs) are highly effective in patients with microsatellite...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : J Immunother Cancer

Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. We conducted a prospective cohort to describe the prevalence,...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma

AbstractIn metastatic pancreatic adenocarcinoma, a high neutrophil-to-lymphocyte ratio (NLR) at diagnosis is a marker of...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clin Res Hepatol Gastroenterol

FOLFIRINOX De‐Escalation in Advanced Pancreatic Cancer: A Multicenter Real‐Life Study

AbstractBackground: Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Oncologist

Anti-Telomerase CD4 + Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials

AbstractDocetaxel, cisplatin and 5-fluorouracil (DCF) chemotherapy regimen is highly effective in advanced anal squamous...

Posté par : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Int J Mol Sci

Exposure-response analysis of Raltitrexed assessing liver toxicity

AbstractAim: Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Br J Clin Pharmacol

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

AbstractMismatch repair-deficient (dMMR) and/or microsatellite instability-high (MSI) colorectal cancers (CRC) represent...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Int J Cancer

Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group

AbstractBackground: Synchronous prostate cancer (PC) and rectal cancer (RC) is a rare clinical situation. While...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Ann Surg Oncol

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE

AbstractBackground Metastatic Squamous cell Penile Carcinoma (mSCPC) is an orphan disease with a virally induced...

Posté par : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Bull Cancer

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)

AbstractBackground: Preoperative radiochemotherapy (RCT) is recommended in France prior to total mesorectal...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)

AbstractPatients and methods: A post hoc analysis of all pathologic reports from patients with stage III CC...

Posté par : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol

Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin

AbstractAnti-EGFR efficacy in patients with microsatellite instability (MSI) metastatic colorectal cancer (mCRC)...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : J Natl Cancer Inst

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

AbstractBackground: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

AbstractBackground: FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal...

Posté par : , Dr. Dewi VERNEREY
Nom de la revue : World J Gastrointest Oncol

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative

AbstractBackground: The variability of definitions for time-to-event (TTE) end-points impacts the conclusions of...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Mme. Julie HENRIQUES
Nom de la revue : Eur J Cancer

01 March, 2020

Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial

AbstractBackground: Despite improvement in colorectal liver metastasis (CLM) treatment, survival after liver...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Ann Surg Oncol

Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study

AbstractBackground: Although no data have been reported beyond second-line therapy, aflibercept is approved in this...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Clin Colorectal Cancer

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]

AbstractIntroduction: Perioperative chemotherapy is the standard strategy for localized gastric cancers....

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Bull Cancer

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

AbstractBackground: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Ann Oncol .

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

AbstractBackground: Patients with RAS wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Oncologist

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan

AbstractBackground: FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Clin Colorectal Cancer

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.

AbstractBACKGROUND:Recurrence patterns in stage III colon cancer (CC) patients according to molecular markers remain...

Posté par : Dr. Dewi VERNEREY,
Nom de la revue : Ann Surg Oncol.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.

AbstractBACKGROUND:Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease....

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Br J Cancer

Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer.

AbstractBACKGROUND:Despite the critical roles of Th1-polarised CD4+ T cells in cancer immunosurveillance, the...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Br J Cancer.

Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.

AbstractPURPOSE:Defective mismatch repair system (dMMR) has been shown to have a favorable impact on outcome in patients...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Int J Radiat Oncol Biol Phys

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials.

AbstractBACKGROUND:We explored and validated the association of postoperative carcinoembryonic antigen (CEA) with...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Cancer Epidemiol Biomarkers Prev

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study.

AbstractIn patients with metastatic colorectal cancer (mCRC), RAS and BRAF mutations are currently determined by tumor...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Cancers

Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy.

AbstractBACKGROUND:Specific surgical and oncological outcomes in patients with rectal cancer surgery after a previous...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Br J Surg

A GERCOR-AERIO national survey of oncology residents in France: Current setting and expectations regarding post-internship and research.

AbstractINTRODUCTION:The demographics of oncology residents has changed since 2010 with the increase in the size of...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Bull Cancer

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study.

AbstractBACKGROUND:Post-transplant diabetes is a frequent and serious complication of kidney transplantation. There is...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Trials

Peritoneal dialysis after kidney transplant failure: a nationwide matched cohort study from the French Language Peritoneal Dialysis Registry (RDPLF)

AbstractBackground: Failed kidney transplant is becoming a frequent cause of dialysis initiation. Although studies...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Nephrol Dial Transplant

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.

AbstractBACKGROUND:The benefit of second-line chemotherapy (L2) over standard first-line (L1) gemcitabine plus cisplatin...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Eur J Cancer.

Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score.

AbstractBACKGROUND:About 5% of pancreatic ductal adenocarcinomas are inherited due to a deleterious germline mutation...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : United European Gastroenterol

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

ABSTRACTBACKGROUND:Two main therapies, pazopanib and sunitinib, are used in the first-line settingfor metastatic renal...

Posté par : , Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Health and Quality of Life Outcomes

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

AbstractBACKGROUND:The incidence of anal squamous cell carcinoma has been increasing markedly in the past few decades....

Posté par : Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).

AbstractBACKGROUND:At time of diagnosis, less than 10% of patients with pancreatic adenocarcinomas (PDAC) are considered...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.

Letter to editor.LINK

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : European Journal of Cancer

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

ABSTRACTBackgroundSunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Trials

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

BACKGROUND:Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : New England Journal of Medicine

3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

ABSTRACTPurpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III...

Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Nom de la revue : Journal of Clinical Oncology

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

BACKGROUND:RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : Ann Oncol

Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies.

BACKGROUND:Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Exp Hematol Oncol

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

BackgroundPatients treated with chemotherapy for microsatellite unstable (MSI) and/or mismatch repair deficient (dMMR)...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

AbstractBackground The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

Since the MOSAIC study, oxaliplatin-based adjuvant chemotherapy has been the standard treatment of stage III colon...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Annals of Oncology

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...

Posté par : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

AbstractBackground: Frailty is highly prevalent in elderly people. While significant progress has been made to...

Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, , Pr. Franck BONNETAIN
Nom de la revue : BMC Geriatrics

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

AbstractBackground: Pancreatic adenocarcinoma (PDAC) incidence is increasing worldwide. Several studies have shown...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : BMC Cancer

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors

AbstractTemozolomide (TEM) showed encouraging results in well-differentiated pancreatic neuroendocrine tumors (WDPNETs)....

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Endocrine-Related Cancer

Value of Donor–Specific Anti–HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss

AbstractThe diagnosis system for allograft loss lacks accurate individual risk stratification on the basis of...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : J Am Soc Nephrol

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score

In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and treatment...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : International Journal of Cancer

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

Background: The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better...

Posté par : Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN
Nom de la revue : British Journal of Cancer

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma

AbstractGlioblastoma is the most common malignant brain tumor in adults. Baselinehealth-relatedquality of life (HRQoL)...

Posté par : , Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN
Nom de la revue : Cancer Medicine

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

Background: Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant...

Posté par : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JNCI Journal of the National Cancer Institure

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients

AbstractBACKGROUND:We investigated whether the health-related quality of life (HRQoL) score is a prognostic factor for...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : EJC

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JCO

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Lancet Oncol

Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study.

AbstractOBJECTIVES:To assess the long term outcomes of transplantation using expanded criteria donors (ECD; donors aged...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMJ

Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies

ABSTRACT Rationale:The role of circulating antibodies in addition to traditional cardiovascular risk factors in...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Test

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

AbstractAIM:Microarray studies identified a subgroup of molecular apocrine tumors (estrogen receptor [ER]...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Future Oncol

Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.

Abstract Background: Baseline prognostic biomarkers stratifying treatmentstrategies in first-line metastatic...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue :

Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.

AbstractOverall survival (OS) has been considered as the most relevant primary endpoint but trials using OS often...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Expert Review of Anticancer Therapy

 Archives

 Contributor